HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry News Roundup

This article was originally published in The Tan Sheet

Executive Summary

‘Heal yourself’ claim nicked by FDA; Urban Moonshine’s error of omission; new tech needs old school substantiation; O2 plans big for InboxFitness; Migranade sprouts spray division; ChromaDex cashes in NeutriSci shares; GoodSense sponsors runDisney; Walgreens joins flu tracking crowd; Qualitas algal omega-3 reaches market; Islet cooks cannabidoil in business plan; and Food Advisory Committee candidates sought.

You may also be interested in...



In Brief

Ramirez appointed FTC chair; budget sequester slows FDA travel, training; ChromaDex divests BluScience brand; Omega Protein buys whey firm; Vitamin Shoppe absorbs integration costs; Vitacost trims net loss in Q4; chemical regulation champion Lautenberg to retire; USANA expands in China.

Investors Go Beserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel